Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 17, 2026, Citius Pharmaceuticals, Inc. (the “Company”) received formal notice that the Nasdaq Stock Market LLC (“Nasdaq”) granted our request for an extension through February 8, 2027 (the “Extension Notice”) to evidence compliance with the $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”…

Results of Operations and Financial Condition. On August 14, 2026, Citius Pharmaceuticals, Inc. issued a press release announcing its results of operations for the third quarter of fiscal 2026. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise sub…

Results of Operations and Financial Condition. On May 15, 2026, Citius Pharmaceuticals, Inc. issued a press release announcing its results of operations for the second quarter of fiscal 2026. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subje…

Entry into a Material Definitive Agreement. On May 4, 2026, in connection with an equity financing transaction and debt facility by Citius Oncology, Inc. (“Citius Oncology”), the majority-owned subsidiary of Citius Pharmaceuticals, Inc. (the “Company”), the Company and Citius Oncology entered into a Third Amendment to Promissory Note (the “Third Amendment”), which amends the promissory note, dated August 16, 2024, as previously amended on September 10, 2025 and December 10, 2025, issued by th…

Unregistered Sales of Equity Securities. As previously disclosed, Citius Pharmaceuticals, Inc. (the “Company”) closed a registered direct offering of common stock and a concurrent private placement of pre-funded warrants, common warrants and placement agent warrants. The disclosure set forth under

of the Current Report on Form 8 K filed by the Company on April 24, 2026 is incorporated by reference into this

Entry into a Material Definitive Agreement. On April 23, 2026, Citius Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors for the issuance and sale, in a registered direct offering by the Company (the “Offering”), of 4,730,457 shares of the Company’s common stock, par value $0.001 per share (the “Shares”), and pre-funded warrants to purchase up to 345,686 shares of common stock (the “Pre-funded Warr…

Results of Operations and Financial Condition. On February 13, 2026, Citius Pharmaceuticals, Inc. (the “Company,” “we” or “our”) issued a press release announcing our results of operations for the first quarter of fiscal 2026. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing . On February 9, 2026, Nasdaq Stock Market LLC (“Nasdaq”) notified the Company that for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3…

Results of Operations and Financial Condition. On December 23, 2025, we issued a press release announcing our results of operations for the full year of fiscal 2025. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of t…

Entry into a Material Definitive Agreement. On October 20, 2025, Citius Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with a certain institutional investor for the issuance and sale, in a registered direct offering by the Company (the “Offering”), of 1,460,000 shares of the Company’s common stock, par value $0.001 per share (the “Shares”), and pre-funded warrants to purchase up to 2,513,510 shares of common stock (the “Pre-funded…

Results of Operations and Financial Condition. On August 12, 2025, we issued a press release announcing our results of operations for the third quarter of fiscal 2025. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of…

Entry into a Material Definitive Agreement. On June 9, 2025, Citius Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with a certain institutional investor for the issuance and sale, in a registered direct offering by the Company (the “Offering”), of 540,000 shares of the Company’s common stock, par value $0.001 per share (the “Shares”), and pre-funded warrants to purchase up to 4,380,000 shares of common stock (the “Pre-funded Warra…

Material Modifications to Rights of Security Holders. Effective upon the filing of this report, the one share of Series A Preferred Stock issued on April 17, 2025, by Citius Pharmaceuticals, Inc. (the “Company”), will automatically be redeemed, pursuant to its terms. Upon the redemption, the holder of the Series A Preferred Stock will receive aggregate consideration of $100, which was the original purchase price of the Series A Preferred Stock.

Entry into a Material Definitive Agreement. On June 2, 2025, Citius Pharmaceuticals, Inc. (the “Company”) issued an unsecured promissory note for an aggregate principal amount of $1 million (the “Note”) to PAGODA RESOURCES, INC, a Pennsylvania corporation. The Note is not convertible into any equity securities of the Company. The Note is due and payable on December 2, 2025, and accrues interest at a rate of 15.00% per year, compounded monthly, until the Note is repaid in full. The Company has…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The disclosure provided in

Notice of Delisting or Failure to Satisfy a Continued Listing Rule; Transfer of Listing. On May 29, 2025, Citius Pharmaceuticals, Inc. (the “Company”) received a determination letter (the “Letter”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market notifying the Company that, based upon the closing bid price of the Company’s common stock for the prior 33 consecutive business days, the Company was not in compliance with the requirement to maintain a minimum bid…

Results of Operations and Financial Condition. On May 14, 2025, we issued a press release announcing our results of operations for the second quarter of fiscal 2025. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of t…

Material Modifications to Rights of Security Holders. The information contained under the heading “Certificate of Designation” in

Unregistered Sales of Equity Securities. The information contained in

Entry into a Material Definitive Agreement. On April 17, 2025, Citius Pharmaceuticals, Inc. (the “Company”) entered into a Subscription and Investment Representation Agreement (the “Subscription Agreement”) with Leonard Mazur (the “Purchaser”), the Chairman and Chief Executive Officer of the Company, pursuant to which the Company agreed to issue and sell one share of the Company’s newly designated Series A Preferred Stock, par value $0.001 per share (the “Series A Preferred Stock”), to the Pu…

Entry into a Material Definitive Agreement. As previously reported, in September 2021, Citius Pharmaceuticals, Inc. (“Citius Pharma”), which owns approximately 92% of the outstanding common stock of Citius Oncology, Inc. (“Citius Oncology”), announced that it had entered into an asset purchase agreement with Dr. Reddy’s Laboratories SA (“Dr. Reddy’s”) to acquire its exclusive license of E7777 (denileukin diftitox). Dr. Reddy’s had previously exclusively licensed E777 in select markets from Ei…

Entry into a Material Definitive Agreement. On April 1, 2025, Citius Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with a certain institutional investor for the issuance and sale, in a registered direct offering by the Company (the “Offering”), of 465,000 shares of the Company’s common stock, par value $0.001 per share (the “Shares”), and pre-funded warrants to purchase up to 1,274,131 shares of common stock (the “Pre-funded Warr…

Entry into a Material Definitive Agreement. On January 7, 2025, Citius Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors for the issuance and sale, in a registered direct offering by the Company (the “Offering”), of 743,496 shares of the Company’s common stock, par value $0.001 per share (the “Shares”) and warrants (the “Warrants”) to purchase up to 743,496 shares of common stock. The Shares and W…

Results of Operations and Financial Condition. On December 27, 2024, we issued a press release announcing our results of operations for the full year of fiscal 2024. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of t…